Blair William & Co. IL Raises Stock Position in Kenvue Inc. (NYSE:KVUE)

Blair William & Co. IL lifted its position in shares of Kenvue Inc. (NYSE:KVUE) by 0.9% during the 4th quarter, Holdings Channel.com reports. The fund owned 194,250 shares of the company’s stock after buying an additional 1,755 shares during the period. Blair William & Co. IL’s holdings in Kenvue were worth $4,147,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Grove Bank & Trust grew its stake in Kenvue by 438.4% in the 4th quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after acquiring an additional 947 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue in the fourth quarter valued at about $29,000. SRS Capital Advisors Inc. grew its position in shares of Kenvue by 67.4% in the fourth quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the last quarter. Fortitude Family Office LLC increased its stake in shares of Kenvue by 106.6% during the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after purchasing an additional 777 shares in the last quarter. Finally, Versant Capital Management Inc raised its position in shares of Kenvue by 300.8% during the 4th quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock worth $41,000 after purchasing an additional 1,441 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $23.97 on Tuesday. The company has a market cap of $45.80 billion, a price-to-earnings ratio of 45.22, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock’s 50-day moving average is $22.38 and its 200-day moving average is $22.46.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. Equities analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a yield of 3.42%. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Analysts Set New Price Targets

Several equities analysts have weighed in on KVUE shares. Barclays raised their price target on Kenvue from $21.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Thursday, March 27th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research report on Monday, February 3rd. Canaccord Genuity Group lifted their target price on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. UBS Group cut their price target on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. Finally, Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a report on Monday, February 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue has an average rating of “Hold” and a consensus target price of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.